IP Verse

Use Of Myostatin Inhibitors And Combination Therapies - EP3368069

The patent EP3368069 was granted to Scholar Rock on Aug 5, 2020. The application was originally filed on Jun 13, 2017 under application number EP17732001A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3368069

SCHOLAR ROCK
Application Number
EP17732001A
Filing Date
Jun 13, 2017
Status
Granted And Under Opposition
Jul 3, 2020
Grant Date
Aug 5, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

GRUNDMay 4, 2021POHLMANADMISSIBLE
HOFFMANN EITLEApr 28, 2021HOFFMANN EITLEADMISSIBLE

Patent Citations (19) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO2015JP06323-
DESCRIPTIONWO2015US59468-
DESCRIPTIONWO2016US52014-
DESCRIPTIONUS2009031435
DESCRIPTIONUS6172197
DESCRIPTIONUS6291158
DESCRIPTIONUS6582915
DESCRIPTIONUS6593081
DESCRIPTIONUS6696245
DESCRIPTIONUS8399437
DESCRIPTIONWO2016073879
INTERNATIONAL-SEARCH-REPORTWO2013072902
INTERNATIONAL-SEARCH-REPORTWO2016073853
OPPOSITIONEP3368069
OPPOSITIONWO2012024242
OPPOSITIONWO2015195094
OPPOSITIONWO2016073853
OPPOSITIONWO2017049011
OPPOSITIONWO2017120523

Non-Patent Literature (NPL) Citations (29) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Anonymous, "2016 SMA Researcher Meeting Summary: The Changing Landscape of SMA - Cure SMA", 2016 SMA Researcher Meeting Summary: The Changing Landscape of SMA - Cure SMA, (20160822), pages 1 - 5, 2016 SMA Researcher Meeting Summary: The Changing Landscape of SMA - Cure SMA, URL: https://www.curesma.org/2016-sma-researcher-meeting-summary-the-changing-landscape-of-sma/, (20210510), XP055803030-
OPPOSITION- ANONYMOUS, "HIGHLIGHTS OF PRESCRIBING INFORMATION Spinraza (Nusinersen)", FDA label, (20161200), pages 1 - 13-
OPPOSITION- ANONYMOUS, "Scholar Rock Presents First Data for Niche Modulator Inhibiting Myostatin Activation and Announces SRK-015 as Lead Drug Program", SCHOLAR ROCK, (20150900), page 1, URL: https://www.fiercebiotech.com/biotech/scholar-rock-presents-first-data-for-niche-modulator-inhibiting-myostatin-activation-an, XP055808582-
OPPOSITION- Anonymous, "The 2016 Annual SMA Conference is Here! - Cure SMA", The 2016 Annual SMA Conference is Here! - Cure SMA, (20160614), pages 1 - 3, The 2016 Annual SMA Conference is Here! - Cure SMA, URL: https://www.curesma.org/the-2016-annual-sma-conference-is-here/, (20210510), XP055803025-
OPPOSITION- Charlotte J. Sumner, Sergey Paushkin, Chien-Ping Ko, Spinal muscular atrophy - disease mechanism and therapy, ACADEMIC PRESS, (20161024), pages 2PP, 6, 15-19, 351 - 356, XP055808563-
OPPOSITION- CHEN et al., "Considerations for Developing Combination Therapies in SMA", Cure SMA Researcher Meeting, (20160616), pages 1 - 57-
OPPOSITION- CULLY MEGAN, "Beefing up the right splice variant to treat spinal muscular atrophy", Nature Reviews, (20141001), vol. 13, page 725, XP055808596-
OPPOSITION- FIDLER BEN, "Scholar Rock Rolls Up $36M To Move Muscle Drug To Clinical Trials", xconomy, (20160104), pages 1 - 3, URL: https://xconomy.com/boston/2016/01/04/scholar-rock-rolls-up-36m-to-move-muscle-drug-to-clinical-trials/, XP055808586-
OPPOSITION- Hannah K. Shorrock, Thomas H. Gillingwater, "Developmental and Translation of Therapies for Spinal Muscular Atrophy", EMJ Neurol, (20160000), vol. 4, no. 1, pages 64 - 73, XP055808547-
OPPOSITION- Louise R. Rodino-Klapac, Amanda M. Haidet Bs, Janaiah Kota Phd, Chalonda Handy Bs, Brian K. Kaspar Phd, Jerry R. Mendell Md, "Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease", Muscle Nerve, (20090000), vol. 39, pages 283 - 296, XP055808605-
OPPOSITION- SUMNER et al., Spinal Muscular Atrophy, (20161024), pages 1 - 83-
OPPOSITION- FARRAR et al., "Emerging therapies and challenges in spinal muscular atrophy", Ann Neurol, (20170217), vol. 81, no. 3, doi:10.1002/ana.24864, pages 355 - 368, XP055403643
OPPOSITION- Silvia Vai, "Bone and Spinal Muscular Atrophy", Bone, PERGAMON PRESS., OXFORD, GB, GB , (20151001), vol. 79, doi:10.1016/j.bone.2015.05.039, ISSN 8756-3282, pages 116 - 120, XP093165398
OPPOSITION- WHITTEMORE et al., "Inhibition of myostatin in adult mice increases skeletal muscle mass and strength", Biochemical and Biophysical Research Communications, (20030000), vol. 300, doi:10.1016/S0006-291X(02)02953-4, pages 965 - 971, XP002574357
OPPOSITION- Suh Joonho, Kim Na-Kyung, Lee Seung-Hoon, Eom Je-Hyun, Lee Youngkyun, Park Joo-Cheol, Woo Kyung Mi, Baek Jeong-Hwa, Kim Jung-Eun, Ryoo Hyun-Mo, Lee Se-Jin, Lee Yun-Sil, "GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone", Proceedings of the National Academy of Sciences, National Academy of Sciences, (20200303), vol. 117, no. 9, doi:10.1073/pnas.1916034117, ISSN 0027-8424, pages 4910 - 4920, XP055934161
OPPOSITION- Ferrill F Rose; Virginia B Mattis; Hansjörg Rindt; Christian L Lorson, "Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy", Human Molecular Genetics, (20090000), vol. 18, no. 6, doi:10.1093/hmg/ddn426, pages 997 - 1005, XP055403670
OPPOSITION- Ling K K Y; Gibbs R M; Feng Z; C-P Ko, "Severe neuromuscular denervation of clinically relevant muscles in a mouse model of spinal muscular atrophy", Human Molecular Genetics, (20120000), vol. 21, no. 1, pages 185 - 195, XP055574876
OPPOSITION- FENG et al., "Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset", Human Molecular Genetics, (20160301), vol. 25, no. 5, doi:10.1093/hmg/ddv629, XP055403595
OPPOSITION- FENG, ZHIHUA et al., "Pharmacologically induced mouse model of adult spinal muscular atrophy to evaluate effectiveness of therapeutics after disease onset", Human Molecular Genetics, (20160000), vol. 25, no. 5, doi:10.1093/hmg/ddv629, pages 964 - 975, XP055403595
OPPOSITION- Xin Zhao; Zhihua Feng; Karen K Y Ling; Anna Mollin; Josephine Sheedy; Shirley Yeh; Janet Petruska; Jana Narasimhan; Amal Dakka; Ellen M Welch; Gary Karp; Karen S Chen; Friedrich Metzger; Hasane Ratni; Francesco Lotti; Sarah Tisdale; Nikolai A Naryshkin; Livio Pellizzoni; Sergey Paushkin; Chien-Ping Ko; Marla Weetall, "Pharmacokinetics, pharmacodynamics, and efficacy of a small- molecule SMN2 splicing modifier in mouse models of spinal muscular atrophy", Human Molecular Genetics, (20160000), vol. 25, no. 10, doi:10.1093/hmg/ddw062, pages 1885 - 1899, XP055403687
OPPOSITION- ROTH S M; WALSH S, "Myostatin: a therapeutic target for skeletal muscle wasting", Current Opinion in Clinical Nutrition and Metabolic Care, (20040000), vol. 7, doi:10.1097/00075197-200405000-00004, pages 259 - 263, XP009037120
OPPOSITION- SMITH et al., "Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders", Curr Opin Support Palliat Care, (20131200), vol. 7, doi:10.1097/SPC.0000000000000013, pages 352 - 360, XP055254846
OPPOSITION- Naryshkin N A; Weetall M; Dakka A; Narasimhan J; Zhao X; Feng Z; Ling K K Y; Karp G M; Qi H; Woll M G; Chen G; Zhang N; Gabbeta V; Vazirani P; Bhattacharyya A; Furia B; Risher N; Sheedy J; Kong R; Ma J; Turpoff A; C-S Lee; Zhang X; Y-C Moon; Trifillis P; Welch E M; Colacino J M; Babiak J; Almstead N G; Peltz S W; Eng L A; Chen K S; Mull J L; Lynes M S; Rubin L L; Fontoura P; Santarelli L; Haehnke D; Mccarthy K D; Schmucki R; Ebeling M; Sivaramakrishnan M; C-P Ko; Paushkin S V; Ratni H; Gerlach I; Ghosh A; Metzger F, "SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy", Science, (20140000), vol. 345, no. 6197, doi:10.1126/science.1250127, pages 688 - 693, XP055227441
OPPOSITION- WALKER et al., "Biochemistry and Biology of GDF11 and Myostatin: similarities, differences and questions for future investigation", Cir. Res., (20160401), vol. 118, no. 7, doi:10.1161/CIRCRESAHA.116.308391, pages 1125 - 1142, XP055562298
OPPOSITION- Esther Latres et al, "Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice", Skeletal Muscle, BioMed Central Ltd, London, UK, London, UK, (20151009), vol. 5, no. 1, doi:10.1186/s13395-015-0060-8, ISSN 2044-5040, page 34, XP021230308
OPPOSITION- Esther Latres; Jeffrey Pangilinan; Lawrence Miloscio; Roy Bauerlein; Erqian Na; Terra B Potocky; Ying Huang; Mark Eckersdorff; Ashique Rafique; Jason Mastaitis; Calvin Lin; Andrew J Murphy; George D Yancopoulos; Jesper Gromada; Trevor Stitt, "Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice", Skeletal Muscle, (20150000), vol. 5, no. 34, pages 1 - 13, XP021230308
OPPOSITION- Yisrael Sidis, Abir Mukherjee, Henry Keutmann, Anne Delbaere, Miyuki Sadatsuki, Alan Schneyer, "Biological Activity of Follistatin Isoforms and Follistatin-Like-3 Is Dependent on Differential Cell Surface Binding and Specificity for Activin, Myostatin, and Bone Morphogenetic Proteins", Endocrinology, The Endocrine Society, US, US , (20060701), vol. 147, no. 7, doi:10.1210/en.2006-0089, ISSN 0013-7227, pages 3586 - 3597, XP055437868
OPPOSITION- LIU et al., "Activin Receptor Type IIB Inhibition Improves Muscle Phenotype and Function in a Mouse Model of Spinal Muscular Atrophy", PLoS One, (20161121), vol. 11, no. 11, doi:10.1371/journal.pone.0166803, page e0166803, XP055403589
OPPOSITION- Samiah A. Al-Zaidy, Zarife Sahenk, Louise R. Rodino-Klapac, Brian Kaspar, Jerry R. Mendell, "Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy", Journal of Neuromuscular Diseases, IOS Press, (20150902), vol. 2, no. 3, doi:10.3233/JND-150083, ISSN 2214-3599, pages 185 - 192, XP055614609

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents